Life-Science Biotech Growth Strategies: Cultivation and Regulation In Today's Global Marketplace - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Life-Science Biotech Growth Strategies: Cultivation and Regulation In Today's Global Marketplace
To effectively grow in the biotech industry, companies must develop multiphase plans that focus on regulation and efficiency.


Pharmaceutical Technology


Scale-up. Learning how to effectively scale up is a crucial aspect of life-science biotechnology company development. Due to high demand projections in this area, industry professionals must be prepared to adapt. Scale-up acceleration depends largely on the ability to define and control processes that produce similar products as those obtained at small scale. For a smooth transition to occur, industrial engineers assist in the implementation of creating high-tech production processes, while scientists take care of late-stage development, ensuring smooth implementation of final phase (III and IV) clinical trials as well as compliance with regulatory demands.

Partnerships. Along the biotechnology company cultivation path, industry professionals must form partnerships that help them attain their development goals. Companies such as Burrill & Company and LSGPA assist life science companies in the development of these strategic partnerships that provide access to resources, marketing tools, funding, intellectual property licensing, and technologies or other alliances necessary for realizing their business plans.

Regulation. Life-science biotechnology companies must consider strategies for streamlining FDA approval, reimbursement, clinical trial design, product liability, and insurance concerns throughout the entire growth process. This will not only encourage efficiency in terms of commercialization, but it will also help with safety issues and decrease overall liabilities.

Conclusion

The future of life-sciences biotechnology companies in the 21st century is promising. Modern science and medicine in Karl Ereky's "biotechnology age" continue to flourish and revolutionize the manner in which the global community thinks about the healthcare industry. Over the next 10 years, we will undoubtedly continue to see product growth in this area as well as advancements in how these technologies develop from start to finish. INTERPHEX will continue to be a resource and reflect as well as represent cutting-edge thought leaders and technology for the pharmaceutical and biotech markets.

RJ Palermo is the event director for INTERPHEX, tel. 203.840.5924,

Reference

1. http://Biotechnology.Reference.com/. Wikipedia, the free encyclopedia. http:// http://www.reference.com/browse/wiki/Biotechnology (accessed: Jan. 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here